CATARACT – BVI FINEVISION

Good Candidate: Subjects 22 years and older considering intraocular surgery to remove your cataracts
About study: The purpose of the study is to evaluate the safety of the FINEVISION HP Trifocal IOL and how well it works compared to an FDA-approved intraocular lens
Which eye: Both eyes
How long is study: 12 months
Number of visits: 11 visits
Cost to the patient: The study visits, study IOLs and study-related procedures, other than your cataract surgery, will be provided at no cost to you or your insurance company.
Compensation: Up to $550 for completed visits
Co-management: None
Sioux Falls Lead Contact: Elle Malmanger elle.malmanger@vancethompsonvision.com 605-361-7083

CATARACT - RxSight 029

Good Candidate: Subjects Age between 40 and 80 with cataracts affecting their vision
About Study: The purpose of this study is to further evaluate the safety of an approved intra-ocular lens (IOL) called RxSight Light Adjustable Lens (LAL) and a device called Light Delivery Device (LDD)
Which eye: OD or OS, randomized
How long is study: 6 months
How many visits: 7 visits for control group and up to 12 for LAL group
Cost to patient/financial: standard cataract surgery billed to insurance, all study related exams and procedures are no additional cost (i.e. LAL LDD treatments and lock-ins)
Compensation: $450 total, no mileage, fine tune included
Co-management: none
Sioux Falls Lead coordinator: rebekah.tuchscherer@vancethompsonvision.com 605-705-3517
Sioux Falls Secondary coordinator: elle.malmanger@vancethompsonvision.com 605-371-7083

CATARACT - KOWA

Good Candidate: At least 18 years old without clinically significant ocular conditions, other than cataracts, that require medication or surgery and are scheduled to undergo standalone cataract surgery. All lens packages eligible. Patients being treated for glaucoma with single medication are eligible (CAIs and ROCK inhibitors excluded).
About Study: A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week treatment and 14-week extension, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery. This study is to determine if subjects randomized to K-321 have less natural [redacted] loss after cataract surgery.
Which eye: One eye - determined by investigator
How long is study: 4-6 months
How many visits: 9-11 visits
Cost to patient: Patient and insurance company responsible for costs associated with cataract surgery. Patients receive Ripasudil drops free of charge.
Compensation: Patient receives $90 per visit up to a total of $990.
Co-management: No co-management.
Lead Contact: Jason Meyer jason.meyer@vancethompsonvision.com 605-371-7064

GLAUCOMA - Allergan Bitmatoprost

Good Candidate: Subjects with glaucoma or ocular hypertension (high eye pressure)
About study: The purpose of this study is to look into the safety and duration of effect of Bimatoprost Sustained Release (SR) 10 µg in the treatment of glaucoma
glaucoma or ocular hypertension (high eye pressure).
How long is study: approximately 32 months
Number of visits: there will be a total of 36 study visits over a period of approximately 32 months (includes up to a 10 day screening period, up to a 42 day washout period, 18 months of a study treatment period followed by 12 months of extended follow up) [redacted]
Cost to patient: It is not expected for there to be any costs for subjects taking part in this study
Compensation: Subject receives UP TO $700 depending on number of visits.
Co-management- No co-management
Lead Contact- Allie Winter allie.winter@vancethompsonvision.com 605-371-7077

PRESBYOPIC- EYENOVIA

Good Candidate: Subject have reported an age-related gradual loss of your ability to focus on nearby objects, presbyopia.
About Study: The purpose of this study is to test the safety and efficacy of a very small dose (called a "microdose") of the investigational pilocarpine 2% eye solution to see if it temporarily improves near vision.
Which eye: Both eyes
How long is study: 2-4weeks
How many visits: 3 visits
Cost to patient: No cost

Compensation: Up to $600
Co-management: None
Lead Contact: A'lece Mathison
alece.mathison@vancethompsonvision.com

PRESBYOPIC - VISUS Therapeutics, Inc VT-003

Good Candidate: Persons between 45 and 80 years of age and have been diagnosed with presbyopia.
About Study: The purpose of this study is to assess the safety of the study drug, BRIMOCHOLTM PF and Carbachol PF, and their efficacy (whether it works) in people with presbyopia.
Which eye: Both eyes
How long is study: 1 years
How many visits: 6 visits
Cost to patient: No additional costs. You and/or your insurance may be responsible for any routine/standard procedures which are not part of the study.

Compensation: Up to $1,680.00 for completed visits.
Co-management: No co-management
Sioux Falls Lead Contact : Allie Winter
allie.winter@vancethompsonvision.com 605-371-7077

REFRACTIVE - Claris CSB-C20-003

Good Candidate: Subjects 18 years of age and older who have been diagnosed with stage 2 (persistent epithelial defect) or stage 3 (corneal ulcer) Neurotrophic Keratitis (NK)
About Study: The purpose of this study is to compare the safety and effectiveness of the study product, CSB.001 ophthalmic solution 0.1% to placebo when treating stage 2 and 3 Neurotrophic Keratitis.
Which eye: One eye. Study eye determined by your Dr.
How long is study: 2 phases. 8-10 weeks per phase.
How many visits: 2 phases, 9-10 visits per phase. Not all subjects will complete both phases
Cost to patient: No cost to patient
Compensation: up to $2000 for completed visits. (up to $1000 per phase), mileage compensation up to $250/visit if over 50 miles round trip
Co-management: No Co-management
Lead Contact: Brandon Joffer brandon.joffer@vancethompsonvision.com 605-361-7083

REFRACTIVE - Bausch and Lomb 906 Hyperopic LASIK

Good Candidate: At least 22 years old with hyperopia. Sphere range +1.00 D to +4.00 D with or without cylinder up to +2.00 D and max MRSE of +5.00 D. Stable refraction (change of less than or equal to +/- 0.50 D in MRSE) for at least 12 months. UCDVA 20/40 or worse. Pupil size less than 7.0mm.
About Study: A Study to Investigate the Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
Which eye: Both eyes - must agree to emmetropia in both eyes
How long is study: 1 year
How many visits: 9 visits over 12 months.
Cost to patient: Procedure is performed at no cost to patient.
Compensation: Subject will be compensated up to $480.00, in addition to free LASIK.
Co-management: No co-management.
Lead Contact: Brandon Joffer brandon.joffer@vancethompsonvision.com 605-371-7068

3101 West 57th Street
Sioux Falls, SD 57108
(605) 361–EYES (3937)

505 32nd Ave E, Ste. B
West Fargo, ND 58078
(701) 566–5390

1925 N 22nd Ave, Ste. 201
Bozeman, MT 59718
(406) 219–0700

4909 S 118th Street
Omaha, NE 68137
(402) 506–9970

2600 Jefferson Street
Alexandria, MN 56308
(320) 762–2166

1747 Poly Dr
Billings, MT 59102
(406) 294–1994

201 E 4th St. Suite 201
South Sioux City, NE 68776
(531) 625-3941

REFRACTIVE - Alcon Contura LASIK- IIT

Good Candidate: Age 21-38 with myopia up to -8.00 D, with or without cylinder up to 3.00 D, and are eligible for Contura (topo-guided) LASIK. Max treated MRSE: -9.00 D.
About Study: Comparison of visual acuity and quality of life following Contoura with Phorcides compared to WaveLight Wavefront Optimized LASIK.
Which eye: Both eyes
How long is study: 3 months
How many visits: 2 visits
Cost to patient: Patient responsible for all costs associated with LASIK surgery.
Compensation: Patient receives $250 after returning for a 3-Month visit.
Co-management: Patients can do post-operative care where they prefer.
Contacts:
Jason Meyer jason.meyer@vancethompsonvision.com 605-371-7064,
Allie Winter allie.winter@vancethompsonvision.com 605-371-7077,
Brandon Joffer brandon.joffer@vancethompsonvision.com 605-371-7068

REFRACTIVE - Johnson & Johnson Monovision

Good Candidate: Persons at least 40 years of age at enrollment who have myopia (nearsightedness) with or without astigmatism and presbyopia (reduction in focusing ability for near work)
About study: The iDesign system and a STAR S4 IR® Excimer laser System are currently approved as safe and effective for LASIK treatment of myopia with and without astigmatism. The device will be used to plan for and to perform the LASIK treatment.
Which eye: Both eyes
How long is study: 12 months
Number of visits: up to 12 scheduled study visits.
Cost to patient: This procedure is done at no cost to the patient
Compensation: $100 at the 1 month and $300 at the 12 month (study exit)
Co-management: No co-management
Lead Contact: Whitney Burrows whitney.burrows@vancethompsonvision.com 605-371-7042

DROPS - Ocular Therapeutix – Healthy Eyes Dextenza

Good Candidate: Healthy individuals at least 18 years old who are not previously known as steroid responders and have open punctum in both eyes. Will need to refrain from contact lens use for the duration of the study, if applicable

About Study: An open-label, multi-center, bilateral, human factors study to evaluate the utilization and safety of a novel intracanalicular insertion device in healthy subjects.

Which eye: Both eyes

How long is study: 1 month

How many visits: 3 visits

Cost to patient: No cost to patient.

Compensation: Patient receives $100 per visit up to a total of $300.

Co-management: No co-management.

Lead Contact: Brandon Joffer brandon.joffer@vancethompsonvision.com 605-371-7068